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Abstract
We have previously reported that ATPgS, a slowly hydrolyzed analog of ATP, inhibits the activation of human CD4
+ T
lymphocytes by anti-CD3 and anti-CD28 mAb. In this report we have partially characterized the signaling mechanisms
involved in this immunosuppressive effect. ATPgS had no inhibitory effect on CD4
+ T-cell activation induced by PMA
and anti-CD28, indicating that it acts proximally to the TCR. It had no effect on the calcium rise induced by CD3/CD28
stimulation, but inhibited the phosphorylation of three kinases, ERK2, p38 MAPK and PKB, that play a key role in the
activation of T cells. The receptor involved in these actions remains unidentiﬁed.
Abbreviations: 50-FSBA– 50-p-(ﬂuorosulfonyl)benzoyl adenosine; ATPgS–adenosine 50-O-(3-thiotriphosphate); E-NTP-
Dase–ecto-nucleoside triphosphate diphosphohydrolase; ERK–extracellular signal-regulated kinase; mAb–monoclonal
antibody; MAPK–mitogen activated protein kinase; PKA–protein kinase A; PKB–protein kinase B; PMA–phorbol 12-
myristate 13-acetate; TCR–T-cell receptor
Introduction
The appearance of adenine nucleotides in the extracellular
ﬂuids can result from cell necrosis, exocytosis of secretory
granules or efﬂux through membrane transport proteins.
Extracellular nucleotides are rapidly degraded by ecto-
nucleotidases ubiquitously present on the cell surface, in
particular E-NTPDases such as CD39 [1]. The actions of
extracellular nucleotides are mediated by two families of
receptors: the P2X receptors that are ligand-gated ion
channels and the P2Y receptors that are coupled to G-
proteins [1]. So far eight genuine human P2Y receptors
have been identiﬁed and characterized [2]. According to
sequence homology they belong to two distinct subgroups.
On the one hand, P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11
receptors are all coupled to phospholipase C via a Gq/11
protein, while the P2Y11 receptor is additionally coupled to
Gs and adenylyl cyclase stimulation. On the other hand, the
P2Y12, P2Y13 and P2Y14 receptors are coupled to Gi.
Many authors have studied the effects of extracellular
nucleotides on human leukocytes [reviewed in 3], such as
chemotaxis, differentiation, and release of cytokines.
Discrepant effects of adenine nucleotides on lymphocyte
proliferation have been reported in the past. Gregory and
Kern [4] showed that extracellular ATP stimulated the
proliferation of murine thymocytes, whereas Fishman et al.
[5] observed that ATP suppressed the proliferation of
human peripheral lymphocytes, presumably as a result of
its degradation into adenosine. Ikehara et al. observed both
inhibitory and stimulatory effects of ATP on murine
lymphocyte proliferation, depending on the origin of the
cells [6]. ATP had a synergistic effect on the proliferation
of human peripheral blood T cells stimulated by phytohe-
magglutinin, an effect apparently mediated by a P2X
receptor [7]. It is well known that T-cell responses may
greatly differ according to the subpopulation studied.
Recently, we showed that extracellular adenine nucleotides
such as ATPgS inhibit CD4
+ T-cell activation, as reﬂected
by decreased proliferation and secretion of both Th1 and
Th2 cytokines in response to CD3 and CD28 ligation [8].
This inhibitory effect might represent a negative feedback
mechanism at the level of the immunological synapse,
since Mizumoto et al. showed that in CD39
j/j mice ATP
accumulates in the pericellular ﬂuid of T cells following
CD3/TCR- and CD28-mediated activation [9].
The inhibitory effect of ATPgS was associated with an
increaseincAMPmediatedbyanunidentiﬁedP2Yreceptor,
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have recently reproduced the inhibitory effect of ATPgSi n
mouse T cells, but suggested that it results from the
inhibition of ATP hydrolysis by CD39 and not from the
activation of a P2Y receptor [10]. On the other hand
Loomis et al. have recently reported a stimulatory effect of
ATP and ATPgS on the Jurkat T cells, possibly mediated
via the P2X7 receptor and p38 MAPK activation [11].
In order to clarify these apparent discrepancies, we have
investigated the signalling mechanisms of ATPgSi n
human CD4
+ T cells.
Materials and methods
Reagents
ATP, adenosine 50-O-(3-thiotriphosphate) (ATPgS) and
phorbol 12-myristate 13-acetate (PMA) were obtained
from Sigma Chemicals (St. Louis, MO, USA). The anti-
CD3 monoclonal antibody (mAb) OKT3 (Orthoclone
OKT3
\) was provided by Janssen-Cilag (Berchem, Bel-
gium) and the anti-CD28 mAb (clone CD28.2) by BD
Pharmingen (San Diego, CA, USA).
Isolation of resting CD4
+ T cells from peripheral blood
Peripheral blood mononuclear cells (PBMC) were isolated
from buffy coats of healthy blood donors by density
gradient centrifugation on Lymphoprep (Nycomed, Oslo,
Norway). After ﬁve washes in Hank’s balanced salt
solution (HBSS) (Gibco Life Technologies, Paisley, UK)
CD4
+ T cells were isolated from PBMC using the MACS
negative depletion system (Miltenyi Biotec, Auburn, CA).
No contaminating CD8
+ T cells, B cells, monocytes, or
natural killer cells were detected.
CD4
+ T-cell activation
Puriﬁed CD4
+ T cells were cultured in RPMI 1640 medium
(Gibco Life Technologies, Paisley, UK) supplemented with
10% heat-inactivated fetal bovine serum (FCS) from
Hyclone (Logan, Utah), 25 mM Hepes buffer, 2 mM
L-glutamine, 1 mM sodium pyruvate, 50 mgm l
j1 genta-
micin and 50 mM2 - b-mercaptoethanol at 37 -Ci n5 %
CO2. The CD4
+ T cells (1   10
5/well) were activated
either in ﬂat-bottomed 96-well plates pre-coated with the
anti-CD3 mAb (10 mgm l
j1) in the presence of soluble
anti-CD28 mAb (1 mgm l
j1), or with 1 ng ml
j1 phorbol
12-myristate 13-acetate (PMA) plus soluble anti-CD28
mAb (1 mgm l
j1), in presence or absence of ATPgS.
Culture supernatants were harvested after 24 h for mea-
surement of IFN-g (Biosource International, Camarillo,
CA). Each experimental condition was tested in triplicate.
Calcium measurements
Intracellular calcium ([Ca
2+]i) was measured in human
CD4
+ T lymphocytes using the ﬂuorescent Ca
2+ indicator
fura 2-AM. Puriﬁed cells were concentrated at 10
7 ml
j1 in
HBSS (supplemented with 0.1% BSA) and incubated at
37-Cin5%CO 2-humidiﬁed atmosphere with 0.25 mM sul-
ﬁnpyrazone (Sigma), 100 mgm l
j1 pluronic acid F-127
(Molecular Probes, Leiden, The Netherlands) and 10 mM
of fura 2-AM (Molecular Probes), for 30 min at 37 -C.
Cells were then washed once in complete medium or
HBSS-BSA with 0.25 mM sulﬁnpyrazone and resus-
pended at a ﬁnal concentration of 5   10
5 ml
j1 and
placed in a 37 -C water bath for 5 min before stimulation
with nucleotide or antibodies. The cells were excited
alternatively at wavelengths of 340 and 380 nM, and the
emission ﬂuorescence intensity was monitored at 505 nM.
The ratio of the two ﬂuorescence intensities induced by
excitation at the two wavelengths (F340/F380) after
substraction of background ﬂuorescence was used to
monitor changes in [Ca
2+]i.
Immunoprecipitation and Western blot analysis of ERK1/2,
p38 and PKB
Puriﬁed CD4
+ T cells (8   10
6 cells) were pre-incubated
with 100 mM ATPgS for 10 min and then stimulated for
different times in ﬂat-bottomed plates with 10 mgm l
j1
anti-CD3 mAb plus 5 mgm l
j1 soluble anti-CD28 mAb
plus 40 mgm l
j1 goat antibody against mouse immunoglo-
bulins (Sigma). Cells were rapidly pelleted, washed with
HBSS and lysed on ice in 20 mM TrisYHCl pH 7.6, 1%
NP-40, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM
sodium orthovanadate, 1 mM sodium ﬂuoride and protease
inhibitor cocktail from Roche Diagnostics. Lysates were
cleared by centrifugation at 10,000 g for 20 min and
incubated for 2 h at 4 -C with 30 ml of protein G im-
mobilized on Sepharose 4B fast ﬂow (Sigma). The super-
natants were recovered after one centrifugation step at
10,000 g for 10 min. The supernatants were then mixed
with concentrated Laemmli buffer (ﬁnal concentration:
10% (w/v) glycerol, 5% (v/v) b-mercaptoethanol, 2.3% (w/v)
SDS, 62.5 mM TrisYHCl pH 6.8) with proteinase inhibitors
(Roche Diagnostics): 1 mgm l
j1 Leupeptin, 60 mgm l
j1
Pefabloc, 1 mgm l
j1 Aprotinin, and phosphatase inhibitors
(Sigma): 1 mM sodium orthovanadate and 10 mM sodium
ﬂuoride. The protein concentration was determined using the
method of Minamide and Bamburg [12]. The same amount of
protein (20 mg) for each condition was electrophoresed on a
12% SDS-polyacrylamide gel. Proteins were then transferred
overnight at 28 V and 4 -C onto a nitrocellulose membrane
using 20 mM Tris, 154 mM glycine, 20% (v/v) methanol as a
transfer buffer. Immunodetection was achieved using anti-
bodies speciﬁc for total and phosphorylated ERK1/2, p38 or
PKB (all from Cell Signaling Technology, Beverly, MA), and
chemiluminescence detection with horseradish peroxidase
coupled secondary anti-mouse antibody (1:25,000) for
ERK1/2 or anti-rabbit antibody (1:50,000) for p38 and PKB
(both from Amersham Pharmacia Biotech).
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The inhibition of IFN-g secretion by ATPgS involves
signaling events proximal to the TCR
In order to see if the inhibitory action of ATPgSi s
proximal to the TCR stimulation, we have tested other
activators that bypass it, PMA/anti-CD28. As shown in
Figure 1, ATPgS inhibited the secretion of IFN-g in human
CD4
+ T cells after stimulation with anti-CD3 and anti-
CD28, as previously reported [8], but had little inhibitory
effect on IFN-g secretion from T cells activated with PMA
plus anti-CD28.
ATPgS does not affect calcium mobilization in
CD4
+ T cells
We studied the effect of ATPgS on the calcium response
induced by TCR stimulation with anti-CD3 and anti-CD28
mAb crosslinked with goat anti-mouse IgG. ATPgS pre-
treatment, 2 or 10 min (data not shown), did not modify the
calcium response following TCR stimulation (Figure 2). As
previously reported, ATPgS did not increase per se [Ca
2+]i
in human CD4
+ T cells [4].
ATPgS inhibits phosphorylation of ERK1/2, p38 and PKB
We examined the action of ATPgS on anti-CD3/CD28-
induced activation of three known downstream targets,
ERK 1/2, p38 and protein kinase B (PKB) in human CD4
+
T cells. By itself, ATPgS did not modify the phosphory-
lation state of p38, ERK1/2 or PKB (data not shown). In
Figure 2. ATPgS has no effect on the calcium response induced by TCR
stimulation with anti-CD3 and anti-CD28. Cells were loaded with FURA
2-AM, and intracellular calcium mobilization was followed on a
spectroﬂuorometer (LS50B, Perkin Elmer). CD4
+ T lymphocytes were
activated by cross-linking the anti-CD3/anti-CD28 mAb with goat anti-
IgG (4) without (A) or with 100 mM ATPgS added (²) to the cells 2 min
before cross-linking (B). Data are from one representative experiment out
of three.
Figure 3. (A) ATPgS pre-treatment inhibits the phosphorylation of
ERK1/2 (a) and p-38 (b) induced by TCR stimulation with anti-CD3 and
anti-CD28 mAb. ATPgS 100 mM was added to the cells 10 min before
activation with antibodies. The same amount of protein for each condition
was electrophoresed on a 12% SDS-polyacrylamide gel. (B) ATPgS pre-
treatment inhibits the phosphorylation of PKB induced by TCR stimula-
tion with anti-CD3 and anti-CD28 mAb. ATPgS 100 mM was added to the
cells 10 min before activation with antibodies. The same amount of
protein (20 mg) for each condition was electrophoresed on a 12% SDS-
polyacrylamide gel.
Figure 1. ATPgS inhibits IFN-g secretion in primary human CD4
+ T
cells following activation mediated by anti-CD3 plus anti-CD28 but not
by PMA plus anti-CD28. The cells were incubated for 24 h either with
PMA (1 ng/ml) and two concentrations of soluble anti-CD28 (1 or 5 mg/
ml) (A) or with a combination of pre-coated anti-CD3 and soluble anti-
CD28 (1 mg/ml) (B), in the continuous presence or absence of ATPgS, that
was added at the same time as PMA/CD28 or anti-CD3/anti-CD28. In the
absence of stimulation, no IFN-g was detectable in the supernatant (data
not shown). Data represent the mean T S.D. of triplicate experimental
points obtained in one representative experiment of three.
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+ T cells, as shown in Figures 3A and
B, a rapid phosphorylation of ERK2 (p42), p38 and PKB
occurred following stimulation by anti-CD3/CD28 anti-
bodies, while no phosphorylation of ERK1 could be
detected. ATPgS (100 mM) pretreatment strongly inhibited
these phosphorylations (Figure 3).
Effect of other adenine nucleotides on IFN-g secretion
In order to evaluate the hypothesis of Langston et al. [6],
we compared the effects of ATPgS, an inhibitor of E-
NTPDases, with that of known substrates, ATP and ADP.
As shown in Table 1, the secretion of IFN-g following CD3
and CD28 stimulation was inhibited to a similar extent by
ATPgS, ATP and ADP. While these nucleotides induced a
signiﬁcant inhibition of IFN-g secretion in all the experi-
ments, adenosine had only a small effect (33 T 4 and 19 T
5% inhibition) in two experiments out of ﬁve (data not
shown).
Discussion
We have previously reported that ATPgS, a slowly
hydrolyzed analog of ATP, inhibits the activation of human
CD4
+ T lymphocytes by a mixture of anti-CD3 and anti-
CD28 mAb [8]. ATPgS inhibited the cell proliferation,
secretion of both Th1 (IL-2 and IFN-g) and Th2 (IL-5 and
IL-10) cytokines and expression of CD25. This effect was
associated with an increase in cAMP, but was not inhibited
by the PKA inhibitor H-89. These results are consistent
with several reports indicating that the immunomodulatory
action of cAMP is mediated partially by PKA and partially
by other mechanisms [13, 14], but it does not allow to
determine the precise mechanism of ATPgS action. It the
present study we have shown that ATPgS has no inhibitory
effect on CD4
+ T cells activation induced by a combination
of PMA and anti-CD28, indicating that it must act
proximally to TCR activation. However ATPgS was unable
to reduce the increase of [Ca
2+]i induced by the anti-CD3/
anti-CD28 combination. It is now well established that
MAP kinases play a key role in the activation of T cells
during the immune response. Both p38 MAPK and ERK
are activated following TCR stimulation [15, 16] and in-
hibitors of both pathways inhibit the secretion of cytokines
[16, 17]. On the other hand the stimulation of CD28
activates phosphatidylinositol 3 kinase (PI3K) and protein
k i n a s eB( P K B )w h i c hb o t hc o o p e r a t ew i t hT C Rt o
enhance T-cell proliferation and cytokine secretion [18].
We have now shown that ATPgS inhibits the activation of
these three pathways, thus providing an explanation for its
immunosuppressive effect. As previously described [15],
we detected activation only of ERK2 and not ERK1 in
human CD4
+ T lymphocytes. These inhibitory effects
might result from cAMP elevation, although the contribu-
tion of other mechanisms cannot be excluded. Indeed,
although it was initially assumed that cAMP interferes with
TCR-coupled phospholipase C and intracellular Ca
2+ mo-
bilization [19, 20], it now appears that it affects multiple
and independent steps along the activation pathway of
T cells. In particular cAMP has been associated with
inhibition of ERK [21, 22], and PKB [22], but an effect on
p38 MAPK has not yet been described.
Langston et al. have reproduced the inhibitory effect of
ATPgS in mouse T cells, but suggested that it results from
the inhibition of ATP hydrolysis by the E-NTPDase CD39
and not from the activation of a P2Y receptor [10]. That
conclusion was mainly based on a similar inhibitory effect
of 50-FSBA, an irreversible inhibitor of E-NTPDases such
as CD39 [23]. However 50-FSBA can modify covalently nu-
merous ATP-binding proteins. The hypothesis of Langston
et al. [10] would imply that CD39 substrates, ATP or ADP,
have no inhibitory effect or even potentiate the activation
of T cells. However,wehave nowshownthatATPandADP
also inhibited activation of CD4
+ T cells. Contrarily to our
observations, Loomis et al. recently reported a stimulatory
effect of ATP and ATPgS on the Jurkat T cells [11]. In
these cells ATP and ATPgS increased both intracellular
calcium and p38 MAPK phosphorylation, two effects
possibly mediated by the P2X7 receptor [11]. These
ﬁndings are likely to be a peculiarity of the Jurkat cell
line, since in CD4
+ T cells isolated from peripheral human
blood, we observed that ATPgS had no effect on [Ca
2+]i
mobilization and p38 MAPK phosphorylation.
The identity of the receptor(s) mediating the effects of
ATPgS and other nucleotides on CD4
+ T lymphocytes
remains unknown. We have previously reported that the
lack of ATPgS effect on [Ca
2+]i is inconsistent with the
involvement of the P2Y11 receptor, the only P2Y receptor
coupled to Gs [8]. Furthermore 20-deoxy-ATP and AR-
C67085MX, two known agonists of recombinant P2Y11,
had no effect on cAMP in these cells [8]. Recently Feng
et al. made similar observations in human mast cells:
ATPgS inhibited cytokine production and increased cAMP
but not [Ca
2+]i [24]. They also concluded that this response
is unlikely to be mediated by P2Y11. Interestingly various
ectonucleotidases expressed in immune cells have a sig-
nalling function beside their enzymatic activity : f.i. CD73
[25], an ecto-50-nucleotidase, and PC-1 [26], an ecto-
phosphodiesterase/pyrophosphatase. In particular, CD73
plays a co-stimulatory role in T-cell activation, indepen-
Table 1. Effect of ATPgs, ATP and ADP on IFN-g secretion following
CD3 and CD28 stimulation.
Mean % inhibition
of IFN-g secretion
S.D. n
ATPgS (100 mM) 70 8 12
ATP (100 mM) 64 13 3
ADP (100 mM) 72 7 5
Puriﬁed CD4
+ T cells were incubated with mAb, pre-coated anti-CD3 and
soluble anti-CD28 (1 mg/ml), and nucleotides. After 24 h of incubation,
the supernatants were harvested for ELISA. In the absence of stimulation,
no IFN-g was detectable in the supernatant (data not shown). Data
collected from triplicate experimental points were normalized to the
activated condition (anti-CD3 plus anti-CD28) to obtain a percentage of
inhibition of IFN-g secretion (n = number of experiments with different
donors).
380 X. Duhant et al.dently from its enzymatic activity. It could be speculated
that the action of nucleotides on CD4
+ T cells is partially
mediated by an ectonucleotidase rather than by a classical
P2X or P2Y receptor. In that sense, CD39 might also be
involved, but via a signalling action, and not as suggested
by Langston et al. [10] via its enzymatic activity.
In conclusion, we have further characterized the signal-
ling mechanisms involved in the immunosuppressive effect
of ATPgS on human CD4
+ T cells. This nucleotide acts by
inhibiting the TCR signalling, but has no effect on the
calcium rise induced by TCR stimulation. Moreover
ATPgS inhibits the activation of three kinases ERK2, p38
MAPK and PKB that play a role downstream of TCR/
CD28. The inhibition of ERK2 and p38 MAPK is sufﬁcient
to explain inhibition of cytokine secretion. Inhibition of
ERK2 and PKB activation is consistent with a role of
cAMP although the contribution of other mechanisms
cannot be excluded. The receptor involved in the action
of ATPgS remains unidentiﬁed. Our observations suggest
that some nucleotides might be useful as immunosuppres-
sive agents, especially for a topical use.
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